CSF3 and amyotrophic lateral sclerosis: Future studies should consider a recruitmentof patients in earlier stages (probable ALS and probable laboratory supported ALS)in addition to higher doses or longer application of G-CSF, because bothexperimental and clinical data suggest higher doses of G-CSF to be associated withbetter functional neurological outcome [5], [6], [53].